Newsfeeds Archive - Spark Newswire

2 minute read

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression

September 21, 10:04 PM

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)

CYBN

2 minute read

Peru’s Coca Leaf Will Be Used For Research Toward Treating ADHD, Learn The Details

By Lara Goldstein

September 21, 4:46 PM

Magdalena Biosciences, Jaguar Health (NASDAQ: JAGX) and Filament Health (OTCQB: FLHLF)

FLHLF

2 minute read

Enveric Biosciences Nabs U.S. Patent For Novel Psilocybin Derivatives, Details Here

By Lara Goldstein

September 21, 12:00 AM

The U.S. Patent and Trademark Office (USPTO) has issued a new patent granting IP rights for the novel composition of matter and methods of use on the psilocybin-based molecules series EVM301 to its developer, Enveric Biosciences (NASDAQ: ENVB).

ENVB

2 minute read

Oregon’s Voter-Approved Drug Decriminalization Law Under Attack, Ballot Proposal Circulating

By Lara Goldstein

September 20, 9:24 AM

Two petitions are circulating in Oregon to overturn the 2020 voter-approved Measure 110 that decriminalized the simple possession of drugs.

NKE

4 minute read

Psyched: MDMA Trials For PTSD, Congressional Amendments, Scotland’s Consumption Site & More

By Lara Goldstein

September 18, 6:06 PM

Treating PTSD With MDMA Therapy: New Results From MAPS Clinical Study, FDA Submission Next

ATAI

2 minute read

Hope For Postpartum Depression: This Company To Launch Clinical Trial On Next-Gen Psychedelic

By Lara Goldstein

September 18, 4:30 PM

Clinical-stage biopharma company Reunion Neuroscience has received the FDA’s clearance on its Investigational New Drug (IND) application to begin a Phase 2 study of RE104, a novel serotonergic psychedelic compound aimed at treating postpartum depression (PPD.)

MSSTF

2 minute read

Billionaire Steve Cohen Invests $19M In Cybin For Psychedelics R&D, Blake Mycoskie’s $100M Pledge Update

By Lara Goldstein

September 18, 3:10 PM

Billionaire hedge fund and NY Mets owner, Steve Cohen amped up his support for psychedelics R&D through a new investment of nearly $19 million in beneficially owned shares of Cybin Inc. (NYSE: CYBN).

ATAI

3 minute read

Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News

By Lara Goldstein

September 15, 5:14 PM

The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.

NUMIF

2 minute read

Psychedelics Capital Moves: Beckley Waves Raises $3.3M, Clearmind’s $2.25M Public Offering

By Lara Goldstein

September 15, 12:09 PM

Beckley Waves: $3.3 Million Round To Expand Safe & Legal Access To Psychedelic Therapies

CMND

1 minute read

Combining MDMA With Psilocybin Or LSD Could Reduce Difficult Trips, New Study Shows

By Lara Goldstein

September 13, 5:12 PM

Recent peer-reviewed research published in the journal Nature posits that a small dose of MDMA could be helpful against uncomfortable or difficult experiences and amplify positive ones when combined with either psilocybin or LSD.

MNMD